Stephanie Dougan, PhD

Principal Investigator at Dana-Farber Cancer Institute

Speaker

Stephanie Dougan received her PhD in Immunology from Harvard University where she studied lipid antigen presentation by CD1d and NKT cell development with Richard Blumberg. She then performed a postdoctoral fellowship with Hidde Ploegh at Whitehead Institute, where she became adept in somatic cell nuclear transfer and embryo manipulations for the purpose of generating transnuclear and CRISPR genome-modified mice. Dr. Dougan joined the faculty at Harvard Medical School and Dana-Farber Cancer Institute in 2014, where her lab uses unique mouse models to study the immune response to tumors. She is particularly interested in tumors that do not induce a CD8 T cell response at baseline, and has been using pancreatic cancer as a model to develop new immunotherapies for non-T cell infiltrated tumors. As one approach, her lab is using an alpaca antibody-based delivery system for targeting cytokines and other payloads to dense pancreatic tumors

Dr. Dougan is a Pew-Stewart Scholar in Cancer Research, a Bill and Melinda Gates Global Health Innovation Scholar, a Melanoma Research Alliance Young Investigator, and received a Pathway to Leadership Award from the Pancreatic Cancer Action Network and AACR.